Researchers say that a new generation of antibiotics may reduce the patient's use of the drug by as much as half.
The researchers are now from London to develop what they hope will be the first of these drugs, a compound works to treat the disease named disease hospitals (MRSA) or Staphylococcus aureus resistant to methicillin, which infects the nose.
This drug works to attack the bacteria that remain as a result of resistance to antibiotics normal.
Will be the experience of antipsychotic medication on humans next year is expected to show that this drug on the market after 5 years.
In the case of the success of researchers in finding a way to overcome bacterial resistance to antibiotics that could give a boost to the existing anti-rather than dispensed with as soon as the inevitability of disease resistance to it.
And the industry is to the reality of the current antibiotics in the fact that its production will take years of work and research as it does not take 18 months of antibiotics for the development of resistance.
Researchers are currently developing an antibiotic, known as (HT61) in the form of cream to overcome the resistance of Staphylococcus aureus MRSA in the nose is the most important part of spreading the disease in the body.
The many hospitals do a test to see if the bacteria present in the patient before subjected to surgical operations.
However, bacteria are divided into two types, one type of division and fast target antibiotics regular effectively large and the other resistor type which is not divided.
The second type is the one who is hiding in the body and cause a recurrence of infection and may lead to the occurrence of resistance in case of exposure to treatment.
Is the (HT61), and performers who proved effective in laboratory experiments on animals, will be effective against the active type of resistant bacteria.
It is expected to be the experience of treatment of 60 people at the beginning of next year.
The team will also then to attack the bacteria methicillin-resistant cluster once it enters into the human body.
Says a professor of Microbiology Faculty of Medicine, St. George's in London and lead author Professor Anthony Coates research that the drug has proved highly effective against resistant bacteria.
He adds, professor of pharmacology at King's College London Professor Clive Paige, one of the co-authors in the study that the research opens the way to the production of a new family of drug-resistant bacteria may be addressed in many diseases.
Paige says: "may lead us to find a combination of drugs, one targeting bacteria Almnevsma and the other resistant to resistant."
"If we came antibiotic Kalpnceljn and put this medicine with him, it is possible to find a treatment program lasts for two or three days instead of five to seven days, as is the case these days.
The researchers are now from London to develop what they hope will be the first of these drugs, a compound works to treat the disease named disease hospitals (MRSA) or Staphylococcus aureus resistant to methicillin, which infects the nose.
This drug works to attack the bacteria that remain as a result of resistance to antibiotics normal.
Will be the experience of antipsychotic medication on humans next year is expected to show that this drug on the market after 5 years.
In the case of the success of researchers in finding a way to overcome bacterial resistance to antibiotics that could give a boost to the existing anti-rather than dispensed with as soon as the inevitability of disease resistance to it.
And the industry is to the reality of the current antibiotics in the fact that its production will take years of work and research as it does not take 18 months of antibiotics for the development of resistance.
Researchers are currently developing an antibiotic, known as (HT61) in the form of cream to overcome the resistance of Staphylococcus aureus MRSA in the nose is the most important part of spreading the disease in the body.
The many hospitals do a test to see if the bacteria present in the patient before subjected to surgical operations.
However, bacteria are divided into two types, one type of division and fast target antibiotics regular effectively large and the other resistor type which is not divided.
The second type is the one who is hiding in the body and cause a recurrence of infection and may lead to the occurrence of resistance in case of exposure to treatment.
Is the (HT61), and performers who proved effective in laboratory experiments on animals, will be effective against the active type of resistant bacteria.
It is expected to be the experience of treatment of 60 people at the beginning of next year.
The team will also then to attack the bacteria methicillin-resistant cluster once it enters into the human body.
Says a professor of Microbiology Faculty of Medicine, St. George's in London and lead author Professor Anthony Coates research that the drug has proved highly effective against resistant bacteria.
He adds, professor of pharmacology at King's College London Professor Clive Paige, one of the co-authors in the study that the research opens the way to the production of a new family of drug-resistant bacteria may be addressed in many diseases.
Paige says: "may lead us to find a combination of drugs, one targeting bacteria Almnevsma and the other resistant to resistant."
"If we came antibiotic Kalpnceljn and put this medicine with him, it is possible to find a treatment program lasts for two or three days instead of five to seven days, as is the case these days.
ليست هناك تعليقات:
إرسال تعليق